Oncology

Latest News

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg
Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy
December 5th 2016

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy

Immuno-oncology will be an important part of cancer care in the future, but probably not the only part, predicted Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network. He also explained how patient advocacy and an enduring healthcare system are essential to the advancement of cancer care.
Site Logo
December 5th 2016

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD
Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.
Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine
December 5th 2016

Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.
Site Logo
December 4th 2016

ASH Symposium on Quality Addresses Health IT Challenges for the Provider and the Patient

Surabhi Dangi-Garimella, PhD
The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.
Site Logo
December 4th 2016

Phase 3 LyMa Trial: Rituximab After ASCT Improves OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD
Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).
Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams
December 4th 2016

Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams

Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.
Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients
December 4th 2016

Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients

A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.
Site Logo
December 3rd 2016

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

Surabhi Dangi-Garimella, PhD
Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.
Site Logo
December 3rd 2016

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

Surabhi Dangi-Garimella, PhD
Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).
David Fabrizio Says Surrogate Endpoints Will Help Accelerate Drug Discovery
December 3rd 2016

David Fabrizio Says Surrogate Endpoints Will Help Accelerate Drug Discovery

Surrogate endpoints, or endpoints other than overall survival, will help accelerate drug discovery and provide additional solutions for patients, according to David Fabrizio, of Foundation Medicine, Inc. However, alternate endpoints are not without their drawbacks.
Dr David Porter Compares Use of CAR T-Cells for B-Cell and Solid Tumors
December 3rd 2016

Dr David Porter Compares Use of CAR T-Cells for B-Cell and Solid Tumors

Chimeric antigen receptor (CAR) T-cells have been dramatically effective in treating B-cell cancers, according to David L. Porter, MD, of the University of Pennsylvania Health System. He also identified the use of CAR T-cells for treating solid tumors as a research area that will see more development in the coming years.
Site Logo
December 2nd 2016

NICE Recommends Pembrolizumab for Advanced Lung Cancer Following Additional Price Cut

AJMC Staff
NICE recommends pembrolizumab for use in advanced lung cancer following additional data review and a further discount in price.
Site Logo
December 2nd 2016

Genomic Changes Ensure Chemotherapy Response in Testicular Cancer

Surabhi Dangi-Garimella, PhD
Research from the Dana-Farber Cancer Institute and the Broad Institute, published in Nature, has identified genomic changes that could explain the development of testicular cancer and why this disease is more responsive to chemotherapy.
This Week in Managed Care: December 2, 2016
December 2nd 2016

This Week in Managed Care: December 2, 2016

This week, the top stories in managed care included the president-elect's picks for HHS and CMS, the American Diabetes Association addressed psychosocial care for patients with diabetes, and the American Society of Clinical Oncology released criteria on creating clinical pathways.
Site Logo
December 1st 2016

Precision CAR-T Trial Shows Early Signs of Success in Multiple Myeloma

Surabhi Dangi-Garimella, PhD
Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.
Site Logo
November 30th 2016

Statins Could Reduce Mortality in Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD
Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.
Site Logo
November 30th 2016

House Committee to Scrutinize the Working of USPSTF

Surabhi Dangi-Garimella, PhD
The House Energy and Commerce Committee's subcommittee on health will gather testimonial from leaders of the US Preventive Services Task Force, the American Academy of Family Physicians, and the American Urologic Association, on a bill called H.R. 1151.
Dr Leonard Fromer Discusses Precision Medicine in Oncology
November 30th 2016

Dr Leonard Fromer Discusses Precision Medicine in Oncology

Cancer patients can now receive individually personalized treatment thanks to algorithms that account for their own unique factors, according to Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.
Site Logo
November 29th 2016

Hospitalization a Major Burden on Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD
A nationally representative study among patients enrolled in Medicare, who were diagnosed with cancer, found that out-of-pocket costs averaged at 23.7% of their household income. A majority of these costs could be attributed to hospitalization.
Site Logo
November 29th 2016

ASCO Framework Can Help Providers Assess Clinical Pathway Programs

Surabhi Dangi-Garimella, PhD
The American Society of Clinical Oncology (ASCO) has released the Criteria for High-Quality Clinical Pathways in Oncology, which is expected to help providers assess the quality, utility, and integrity of pathway programs in the United States.
Site Logo
November 29th 2016

What We're Reading: Warren Says Pharma "Hijacked" Cures Bill

AJMC Staff
What we're reading, November 29, 2016: Warren cries foul over pharma's role in legislation; women fear what will happen to coverage under Trump; and Gallup poll finds most Americans want changes or repeal of the Affordable Care Act.
Site Logo
November 28th 2016

21st Century Cures Set for a Midweek House Vote

Surabhi Dangi-Garimella, PhD
With $372 million carved out for the National Institutes of Health innovation account in 2017, and about $114 million assigned to President Barack Obama’s Precision Medicine Initiative for the fiscal year 2018, the 21st Century Cures Act has a lot at stake for healthcare in the United States.
Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology
November 26th 2016

Kim Eason Explains Horizon's Use of Bundled Payment Model for Oncology

Oncology is a perfect fit for the bundled payment model, because it evaluates the outcomes, patient satisfaction, and cost of an oncology episode, said Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ. She said that Horizon adopted the bundled payment model early to cope with New Jersey’s rising healthcare costs.
Site Logo
November 26th 2016

Mitigating Chemotherapy-Induced Neutropenia With a Novel Same-Day Treatment

AJMC Staff
Trial data on the use of plinabulin for mitigating chemotherapy-induced neutropenia with docetaxel will be presented as a poster at the American Society of Hematology’s annual meeting in San Diego.
Site Logo
November 25th 2016

Risk Factors for Neutropenia and Infections in Childhood ALL

AJMC Staff
A study published in the Annals of Oncology has analyzed data on young patients with acute lymphoblastic leukemia (ALL) to evaluate risk factors for febrile neutropenia and infection-related complications.
The Future of Value-Based Care and Payment Models in Cancer Care
November 24th 2016

The Future of Value-Based Care and Payment Models in Cancer Care

Do APMs Incorporate Survivorship Care in Oncology?
November 24th 2016

Do APMs Incorporate Survivorship Care in Oncology?

Patient Centricity of Care Delivery and Payment Models
November 24th 2016

Patient Centricity of Care Delivery and Payment Models

The Balancing Act of Healthcare Costs
November 24th 2016

The Balancing Act of Healthcare Costs

Innovative Technology and Healthcare Costs
November 24th 2016

Innovative Technology and Healthcare Costs

<1
...
858687888990919293
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo